Dongyao Pharmaceutical-B (01875) rose more than 23%. As of press release, it was up 21.91% to HK$2.17, with a turnover of HK$2,496 million.
The Zhitong Finance App learned that Dongyao Pharmaceutical-B (01875) rose more than 23%. As of press release, it was up 21.91% to HK$2.17, with a turnover of HK$2,496 million.
According to the news, Bailey Tianheng recently announced that its wholly-owned subsidiary SysTimmune and Bristol-Myers Squibb (BMS) have reached an exclusive license and cooperation agreement on the BL-B01D1 (EGFR × HER3 dual antibody ADC) project. Huajin Securities said earlier that it is recommended to focus on the layout of next-generation ADC technology platforms, innovative pharmaceutical companies with advanced ADC development/commercialization, and ADC CDMO innovative pharmaceutical companies, such as Dongyao Pharmaceutical.
Anxin International previously stated that in the first half of 2023, the company's CDMO revenue was 46.55 million, an increase of 105% over the previous year. There are 45 ongoing projects, including 28 ADC projects, and 20 new projects were added in the first half of this year. Of these, 15 are ADC projects, including 3 new pre-BlaADC projects. The bank believes that the company, as a leader in the domestic ADC CDMO field, is expected to receive dividends from this industry, and suggests keeping an eye on it.